New Beijing News (Reporter Zhang Zhaohui) On August 1st, AbbVie announced that the European Commission (EC) has approved SKYRIZI (risankizumab) for the treatment of moderate to severe active ulcerative colitis in adult patients who have insufficient response, loss of response, or intolerance to traditional drug or biological therapy.
Ulcerative colitis is a chronic, unpredictable, and sometimes even debilitating disease, and people with ulcerative colitis need sustained symptom relief. It is estimated that ulcerative colitis affects 5 million people worldwide, and the global incidence rate is rising. The common signs and symptoms of ulcerative colitis include diarrhea, abdominal pain, bloody stools, urgency to defecate, mucous stools, and rectal pain and bleeding. Due to pain and discomfort, patients often lack the ability or desire to engage in daily activities.
In INSPIRE and COMMAND studies, patients receiving SKYRIZI treatment achieved significant improvements in clinical remission and mucosal healing. Research has found that mucosal healing not only goes beyond symptom control, but also involves the repair of the intestinal wall and is associated with improving long-term outcomes.